MIM
ELOX

MetLife Investment Management’s Eloxx Pharmaceuticals, Inc. Common Stock ELOX Stock Holding History

MetLife Investment Management’s Portfolio ELOX Stock Details ELOX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-360
Closed -$144K – 2421
2019
Q2 		$144K Hold
360
– – ﹤0.01% 2211
2019
Q1 		$168K Hold
360
– – ﹤0.01% 2064
2018
Q4 		$173K Hold
360
– – ﹤0.01% 1986
2018
Q3 		$245K Buy
+360
New +$230K ﹤0.01% 1966

Other funds holding ELOX

MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AS
Altshuler Shaham Tel Aviv, Israel $5.54B AUM 44.68% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MIH
Meitav Investment House Bene-Beraq, Israel $14.9B AUM 46.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

MetLife Investment Management's ELOX Position: Q3 2019 in Review

MetLife Investment Management sold out of Eloxx Pharmaceuticals, Inc. Common Stock (ELOX) in Q3 2019, closing a stake of 360 shares — an estimated $144K sold.

MetLife Investment Management first reported a position in ELOX in Q3 2018 and held it in 4 quarters. The position peaked at $245K in Q3 2018. 48 funds tracked by Wall St. Rank hold ELOX as of Q3 2019.

  • MetLife Investment Management reported no remaining Eloxx Pharmaceuticals, Inc. Common Stock position as of Q3 2019 after selling out during the quarter.
  • MetLife Investment Management sold 360 Eloxx Pharmaceuticals, Inc. Common Stock shares in Q3 2019, an estimated $144K.
  • MetLife Investment Management first reported a position in Eloxx Pharmaceuticals, Inc. Common Stock in Q3 2018 and held it in 4 quarters.
  • MetLife Investment Management's Eloxx Pharmaceuticals, Inc. Common Stock position peaked at $245K in Q3 2018.
  • 48 funds tracked by Wall St. Rank held Eloxx Pharmaceuticals, Inc. Common Stock as of Q3 2019.

Based on MetLife Investment Management's 13F filing for Q3 2019, filed 14 Nov 2019.